comparemela.com

Latest Breaking News On - நிறுவனம் ஆஃப் சிறுநீரக புற்றுநோயியல் - Page 1 : comparemela.com

Cabozantinib most effective treatment for metastatic papillary kidney cancer

 E-Mail IMAGE: Sumanta Pal, MD, a SWOG Cancer Research Network researcher and City of Hope physician, led a study that sets a new standard of care for metastatic papillary kidney cancer view more  Credit: City of Hope In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer - findings expected to change medical practice. These findings will be presented at ASCO s virtual 2021 Genitourinary Cancers Symposium on Feb. 13, 2021 at 1 p.m. ET. The findings will be simultaneously published in

Researcher receives award to investigate new stromal biomarker for prostate cancer

UCLA Jonsson Comprehensive Cancer Center Dr. Jeremie Calais December 16, 2020 Dr. Jeremie Calais, assistant professor of nuclear medicine and theranostics in the department of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA, is one of 26 researchers to be named a 2020 Young Investigator by the Prostate Cancer Foundation. In recognition of innovative prostate cancer research, the Young Investigator Award is given to the next generation of cancer researchers who are committed to advancing the prostate cancer field. Calais, who is trained in nuclear medicine and cancer imaging, was awarded the Larry Ruvo-PCF Young Investigator Award and $225,000 to help support his work investigating a PET imaging tracer that targets the fibroblast activation protein, or FAP, expressed on fibroblasts within the tumor stroma or on cancer-associated fibroblasts. Validating a biomarker for FAP expression may help guide treatment decisions for men with prostate cancer,

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.